Clearmind Medicine Price to Free Cash Flow Ratio 2023-2025 | CMND

Clearmind Medicine price to free cash flow ratio from 2023 to 2025. Price to free cash flow ratio can be defined as

Clearmind Medicine Price to Free Cash Flow Ratio 2023-2025 | CMND

Clearmind Medicine price to free cash flow ratio from 2023 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.9B
Zoetis (ZTS)$70.1B
Daiichi Sankyo, - (DSNKY)$43.9B
Takeda Pharmaceutical (TAK)$43.7B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$18.3B
Astellas Pharma (ALPMY)$17.4B
United Therapeutics (UTHR)$17B
Summit Therapeutics (SMMT)$15.9B
Shionogi (SGIOY)$12.3B
Neurocrine Biosciences (NBIX)$11.4B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.5B
Orion OYJ (ORINY)$7.4B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Stevanato Group S.p.A (STVN)$6.2B
Grifols, S.A (GRFS)$5.1B
Ionis Pharmaceuticals (IONS)$5B
Ono Pharmaceutical (OPHLF)$4.7B
Recursion Pharmaceuticals (RXRX)$4.2B
Crinetics Pharmaceuticals (CRNX)$3.4B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
Hypermarcas (HYPMY)$2.2B
Centessa Pharmaceuticals (CNTA)$2.1B
Soleno Therapeutics (SLNO)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
NewAmsterdam Pharma (NAMS)$1.8B
Evotec AG (EVO)$1.6B
Ardelyx (ARDX)$1.5B